Ekso Bionics® Launches EksoPulse Cloud-Based Analytics
February 09 2017 - 8:00AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, today announced the worldwide launch of EksoPulse, an
advanced cloud-based information technology platform that enhances
the clinician, institutional and patient experience with the Ekso
GT™ robotic exoskeleton. EksoPulse operates in conjunction with
technologies from leading global companies to support the new
system with EksoPulse Analytics.
The new EksoPulse platform technology uniquely
allows physical therapists (PTs) to personalize patient care with
the Ekso GT. The technology allows PTs to not only capture
patient progress during sessions, but to store the therapeutic data
in a cloud-based system, to synchronize that data with cellular
technology in order to track changes in patient performance and to
then make real-time adjustments to care plans. Key features
of EksoPulse include enhanced data analytics, cellular data
transmission and cloud-based data storage capabilities, which allow
a physician or PT to access rehabilitation measures via a secure
web-based portal.
“The proprietary EksoPulse technology allows our
customers to offer personalized care and rehabilitation for their
patients by analyzing each individual’s utilization on the Ekso
GT,” commented Thomas Looby, president and chief executive officer
of Ekso Bionics. “We are committed to continuous innovation and
enhancements in our technology and to positively impacting the
well-being of patients.”
EksoPulse is commercially available to
rehabilitation centers around the world that are using the newest
generation Ekso GT with SmartAssist, a comprehensive gait therapy
software. The data from EksoPulse can be reviewed on the
portal by users through a PC or Mac and clinicians can access
patient information at any time to make informed decisions, which
could have a significantly positive impact on patient care and
recovery.
"Using EksoPulse lets me objectively track a
patient's progress. It saves me time because I know each session's
data is accurately documented and the filtering tools make it quick
and easy to find an individual's records," commented Antoinette
Domingo, PT, PhD, Assistant Professor in the Doctor of Physical
Therapy Program at San Diego State University.
Ekso Bionics will have presentations and
demonstrations and will also be showcasing the Ekso GT with
EksoPulse at the following conferences:
Association of Academic Physiatrists (AAP) 2017
Meeting
- February 7-11, 2017 – Las Vegas, Nevada
- Live Demonstrations: Booth #432
- Lunch Symposium: February 9 – 12:30 - 1:30 pm; Exhibit Hall /
Dining Area
American Physical Therapy Association Combined
Sections Meeting (CSM) 2017:
- February 15-18, 2017 - San Antonio, Texas
- Hands-on Workshop for SmartAssist: Booth #342
- Afterhours Event: February 16 – 5:00 - 6:30 pm; Booth #342
To learn more about EksoPulse or Ekso GT, visit
www.eksobionics.com
About Ekso Bionics® Ekso Bionics
is a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical, industrial and defense applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe, to providing
research for the advancement of R&D projects intended to
benefit U.S. defense capabilities. The company is headquartered in
the Bay Area and is listed on the Nasdaq Capital Market under the
symbol EKSO. For more information,
visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first exoskeleton cleared by
the FDA for use with stroke and spinal cord injuries from
L5 to C7. The Ekso GT with SmartAssist™ software is the only
exoskeleton available for rehabilitation institutions that can
provide adaptive amounts of power to either side of the patient’s
body, challenging the patient as they progress through their
continuum of care. The suit’s patented technology provides the
ability to mobilize patients earlier, more frequently and with a
greater number of high intensity steps. To date, this device has
helped patients take more than 55 million steps in over 130
rehabilitation institutions around the world.
Forward-Looking Statements Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iii) the Company's future financial performance
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, changes resulting from the Company’s finalization of
its financial statements for and as of the period and year ended
December 31, 2016, information or new changes in facts or
circumstances that may occur prior to the filing of the Company’s
Annual Report on Form 10-K that are required to be included
therein, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
our technology, the significant length of time and resources
associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the
Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us
at www.eksobionics.com. The Company does not undertake to
update these forward-looking statements.
Media Contact:
Carrie Yamond/Rajni Dhanjani
212-867-1788
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024